© PR Newswire
09.12.2025
6472
LISTED
TAI
Bora Pharmaceuticals and Corealis Pharma Forge Strategic Alliance to Deliver Seamless, End-to-End Oral Solid Dose Development
News Preview
Partnership creates simplified pathway from early development to commercial launchMAPLE GROVE, Minn., Dec. 9, 2025 /PRNewswire/ -- Bora Pharmaceuticals Co., Ltd. ("Bora", TWSE: 6472), a global leader in pharmaceutical manufacturing, and Corealis Pharma Inc., a leading early-phase Contract Development Manufacturing Organization (CDMO), have entered...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
CTXR
LISTED
NASDAQ
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
News Preview
Proceeds strengthen cash position and support commercial launch of LYMPHIR™, a novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL)CRANFORD, N.J., Dec. 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasd...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
GILD
LISTED
NASDAQ
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
News Preview
Gilead Foundation today announced a commitment of more than $3 million in new grants to help address critical gaps in education, care delivery and support services for people affected by metastatic breast cancer (mBC). Building on more than $21 million in support since 2021, funding distributed through the Gilead Foundation advances efforts to imp...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
09.12.2025
HCA
LISTED
NYSE
HCA Healthcare Names Virginia Tenpenny Vice President of Community Engagement
News Preview
HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that Virginia Tenpenny has been named vice president of community engagement, effective January 12, 2026.
In this role, Tenpenny will lead HCA Healthcare’s community engagement strategy, overseeing a team that manages social and charitable investmen...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
09.12.2025
ALC
LISTED
NYSE
Alcon Announces Amended Merger Agreement with STAAR Surgical
News Preview
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into an amended merger agreement for the acquisition of STAAR Surgical Company (NASDAQ: STAA, “STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision corr...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
TEM
LISTED
NASDAQ
Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS). The meeting takes place December 9–12 at the Henry B. González Convention Center in San Antonio, Texas.
“This...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
ADVM
LISTED
NASDAQ
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
News Preview
INDIANAPOLIS, Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the tender offer (the "Offer") by Flying Tigers Acquisition Corporation ("Purchaser"), a direct wholly-owned subsidiary of Lilly, to purchase all of the issued and outstanding shares ("Shares") of Adve...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
QCLS
LISTED
NASDAQ
Quantum-Class Computing Developer Q/C Technologies Welcomes Strategic Advisor Martin Shkreli
News Preview
New York, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (Nasdaq: QCLS) (“Q/C” or “the Company”), a pioneer of quantum-class computing at the speed of light, today announced that Martin Shkreli become a Strategic Advisor to the Company, contributing his experience in technology, industry contacts, financial innovation and early-stage gr...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
GH
LISTED
NASDAQ
Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guar...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
TFX
LISTED
NYSE
Teleflex Announces Sale of Acute Care, Interventional Urology, and OEM Businesses for $2.03 Billion
News Preview
Board of Directors authorizes new $1 billion share repurchase program Board of Directors authorizes new $1 billion share repurchase program...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
LUCD
LISTED
NASDAQ
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
News Preview
Report includes nearly 12,000 patients who underwent Lucid's EsoGuard® Esophageal DNA Test on samples collected using its EsoCheck® Esophageal Cell Collection DeviceReal-world data confirm excellent technical performance, very rapid cell-collection times, and appropriate physician use, consistent with previously published studiesNEW YORK, Dec. 9,...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
09.12.2025
ATOS
LISTED
NASDAQ
Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen
News Preview
New patent further strengthens global intellectual property estate supporting Atossa's lead program across the breast cancer spectrum and other hormone-driven conditionsSEATTLE, Dec. 9, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapi...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
MYGN
LISTED
NASDAQ
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
News Preview
Myriad Genetics will present new data in eight abstracts at the 2025 San Antonio Breast Cancer Symposium (SABCS)....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
HQY
LISTED
NASDAQ
Young Americans Lead in HSA Adoption But Carry Heaviest Economic Burden, HealthEquity Research Finds
News Preview
New Healthcare Affordability Pulse Reveals Generational Divide in Financial Preparedness and Workplace stress New Healthcare Affordability Pulse Reveals Generational Divide in Financial Preparedness and Workplace stress...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
BNBX
LISTED
NASDAQ
BNB Plus Provides BNB Treasury and Operational Updates
News Preview
BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today provided a corporate update highlighting its recent strategic treasury growth, expected significant narrowing of losses at its LineaRx, Inc. (“LineaRx”) subsidiary, and the launch of a new corporate website and branding.
Significant Addition to BNB Treasury
The Company has opportunis...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced that dosing of ALS patients in the Company’s ALSTARS Trial of COYA 302 has commenced.
Dr. Fred Grossman, the...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
ENVB
LISTED
NASDAQ
Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates
News Preview
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for a patent application per...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
NTRA
LISTED
NASDAQ
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today shared the results from two oral presentations that were presented at the American Society of Hematology (ASH) Annual Meeting.
Real-world Signatera Analysis: Oral Presentation on December 6
A real-world analysis of personalized circulating tumor DNA (ctDN...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
SLP
LISTED
NASDAQ
Simulations Plus Positioned to Capitalize on FDA’s Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today responded to the U.S. Food and Drug Administration’s draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies. The guidanc...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
LNAI
LISTED
NASDAQ
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market
News Preview
SACRAMENTO, Calif., Dec. 9, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotechnology company developing precision therapeutics, today announced the identification of three clinically relevant Parkinson's disease subtypes and prioritized drug targets that may accelerate proof-of-concept programs, derisk therapeutic developmen...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
JNJ
LISTED
NYSE
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
News Preview
TECVAYLI® and DARZALEX FASPRO® combination led to a statistically significant progression-free survival and overall survival advantage compared to standard treatment after three years of follow-upCombination regimen granted Breakthrough Therapy Designation by U.S. FDAORLANDO, Fla., Dec. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
ELAN
LISTED
NYSE
Elanco Investor Day Defines New Era as Sustainable Growth Company
News Preview
Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and low double-digit adjusted EPS growth, all starting in 2026. Expects further net leverage ratio improvement to <3x in 2027, with a long-term target o...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
CLTX
LISTED
NASDAQ
Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
News Preview
Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival rates ...
Themefolio
Profiler
Peergroup
© Newsfile
09.12.2025
OSTX
LISTED
XASE
OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
News Preview
Alignment achieved on all key points surrounding non-clinical, CMC and post-market authorization confirmatory study designBiomarker data advanced as key pre-specified surrogate clinical efficacy endpoint, with pending analysis awaiting alignment with US FDA on biomarker statistical analysis plan to be discussed at upcoming December 11, 2025 FDA Typ...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
LLY
LISTED
NYSE
Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
News Preview
The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal of Clinical Oncology and highlighted in a late-breaking oral presentation at the 2025 American Society of Hematology Annual Meeting and Exposition,...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
APRE
LISTED
NASDAQ
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
News Preview
Financing from new and existing healthcare focused investors...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
ICLR
LISTED
NASDAQ
ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive
News Preview
ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market. In total, both surveys captured...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
MBRX
LISTED
NASDAQ
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026
News Preview
Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking within expected range...
Themefolio
Profiler
Peergroup
© EQS Newswire
09.12.2025
FYB
LISTED
XETR
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
News Preview
Presse Release // December 09, 2025
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful lau......
Themefolio
Profiler
Peergroup
© EQS Newswire
09.12.2025
FYB
LISTED
XETR
Formycon und Zydus schließen exklusive Lizenz- und Liefervereinbarung für FYB206, ein Biosimilar für Keytruda® (Pembrolizumab), in den USA und Kanada
News Preview
Pressemitteilung // 09. Dezember 2025
Formycon und Zydus schließen exklusive Lizenz- und Liefervereinbarung für FYB206, ein Biosimilar für Keytruda® (Pembrolizumab), in den USA und Kanada
Lizenzpartner Zydus verfügt über umfangreiche kommerzielle Erfahrung und vermarktet mehr als 225 von der FDA zugelassene Medikamente – eine starke Ausgangsbasi......
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
CLDX
LISTED
NASDAQ
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
News Preview
HAMPTON, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the initiation of its global Phase 3 trial (EMBARQ-ColdU and SD) designed to establish the efficacy and safety of barzolvolimab in adult patients with cold urticaria (ColdU) and symptomatic dermographism (SD) who remain symptomatic despite H1 antihistamine trea...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
CYPH
LISTED
NASDAQ
Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor
News Preview
CAMBRIDGE, Mass., Dec. 9, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) today announced that industry pioneer Zooko Wilcox, the founder of Zcash, former CEO of the Electric Coin Company, and current Chief Product Officer of Shielded Labs, has joined the company as a Strategic Advisor.
Zooko brings a decades-long track record of...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
CYPH
LISTED
NASDAQ
Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor
News Preview
CAMBRIDGE, Mass., Dec. 9, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) today announced that industry pioneer Zooko Wilcox, the founder of Zcash, former CEO of the Electric Coin Company, and current Chief Product Officer of Shielded Labs, has joined the company as a Strategic Advisor.
Zooko brings a decades-long track record of...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
CYPH
LISTED
NASDAQ
Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor
News Preview
CAMBRIDGE, Mass., Dec. 9, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) today announced that industry pioneer Zooko Wilcox, the founder of Zcash, former CEO of the Electric Coin Company, and current Chief Product Officer of Shielded Labs, has joined the company as a Strategic Advisor.Zooko brings a decades-long track record of s...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
GRIN
LISTED
CSE
Grown Rogue Secures Cultivation Facility in Minnesota
News Preview
Location Approved for Cannabis Cultivation; Construction Planned in 2026 with First Product Anticipated in Early 2027MEDFORD, Ore., Dec. 9, 2025 /CNW/ - Grown Rogue International Inc. ("Grown Rogue" or the "Company") (CSE: GRIN) (OTC: GRUSF), a flower-forward cannabis company combining craft values with disciplined execution, today announced that...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
CYPH
LISTED
NASDAQ
Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor
News Preview
CAMBRIDGE, Mass., Dec. 9, 2025 /CNW/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) today announced that industry pioneer Zooko Wilcox, the founder of Zcash, former CEO of the Electric Coin Company, and current Chief Product Officer of Shielded Labs, has joined the company as a Strategic Advisor.Zooko brings a decades-long track record of shaping...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
CBLL
LISTED
NASDAQ
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution
News Preview
Novel technology paves the way for use of the company's industry-leading point-of-care electroencephalography (EEG) system to address long unmet need in delirium monitoring Novel technology paves the way for use of the company's industry-leading point-of-care electroencephalography (EEG) system to address long unmet need in delirium monitoring...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
LBRX
LISTED
NASDAQ
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices
News Preview
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the Company has been included in the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets on December 22, 2025, as part of the 2025 Russell indexes reconsti...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
IPSC
LISTED
NASDAQ
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors
News Preview
PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced the appointments of Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its Board of Directors. As...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
TEVA
LISTED
TLV
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
News Preview
PARSIPPANY, N.J. and TEL AVIV, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for olanzapine extended-release injectable suspension (TEV-'749)...
Themefolio
Profiler
Peergroup
© Newsfile
09.12.2025
MUSL
LISTED
CSE
Promino Announces Secured Convertible Debenture Offering for Proceeds of up to $1 Million
News Preview
Burlington, Ontario--(Newsfile Corp. - December 9, 2025) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FSE: 93X) ("Promino" or the "Company") announces it intends to complete a non-brokered private placement of secured convertible debentures (the "Convertible Debentures") of the Company for an aggregate principal amount of up to $1...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
PLSE
LISTED
NASDAQ
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology
News Preview
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced a research collaboration with The University of Texas MD Anderson Cancer Center to examine the use of the Company...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
PEPG
LISTED
NASDAQ
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen’s 2024 Inducement Plan as a material inducement to employment to its...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
XNCR
LISTED
NASDAQ
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
News Preview
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the issuance of U.S. Patent 12,492,253, which covers Xencor’s Xtend™ Fc domain for extending the half-life of antibodies targeting C5, with a term that extends into December 20...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
45680
LISTED
XJPX
DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer
News Preview
The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy in patients with HER2 expressing (IHC 3+/2+/1+) advanced high-grade epithelial ovarian cancer following trea...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
2196
LISTED
HKSE
Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement
News Preview
SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Un...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
TECH
LISTED
NASDAQ
Bio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis
News Preview
Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexingEnables up to 24 targets per sample and supports complex assay configurationsStrengthens Bio-Techne's leadership in proteomic analytical instruments and supports 21 CFR Part 11 complianceMINNEAPOLIS, De...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
CVS
LISTED
NYSE
CVS Health Updates Financial Guidance, Highlights Strength of Businesses, and Announces Strategy to Uniquely Reimagine Health Care at Investor Day Event
News Preview
Outlines strategy to deliver best-in-class execution, transform consumer experiences, be the partner of choice, and harness unique enterprise capabilities Updates 2025 full-year financial guidance; provides 2026 full-year financial guidance Commits to mid-teens Adjusted EPS CAGR through 2028 Announces strategy to uniquely reimagine health care thr...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
CRON
LISTED
TSX
Cronos to enter the Netherlands with acquisition of Europe’s largest adult-use cannabis company
News Preview
Cronos to acquire CanAdelaar for up-front cash consideration of US$67.0M1 plus cash earnout of 0.5x normalized EBITDA in 2026 and 2027...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
BCT
LISTED
TSX
BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
News Preview
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce its Phase 3 clinical study has screened over 230 and en...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
PFE
LISTED
NYSE
Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
News Preview
Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited (02196.HK and 600106.SH), a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002,...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
FYB
LISTED
XETR
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
News Preview
PLANEGG-MARTINSRIED, Germany and AHMEDABAD, India, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Formycon AG (FSE: FYB, “Formycon”) and Zydus Lifesciences Limited (including its subsidiaries and affiliates, “Zydus”), today jointly announced that they have entered into a strategic partnership for the exclusive licensing and supply of checkpoint inhibitor FYB2...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
IRD
LISTED
NASDAQ
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
News Preview
Initial favorable safety profile demonstrated in OPGx-BEST1 clinical trial Initial favorable safety profile demonstrated in OPGx-BEST1 clinical trial...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
FRX
LISTED
TSX
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
News Preview
– City of Hope to Evaluate PEDMARK® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors –...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
CSTL
LISTED
NASDAQ
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
News Preview
Castle Biosciences announced the publication of an independent expert consensus paper endorsing the Company’s DecisionDx-Melanoma test....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
TNXP
LISTED
NASDAQ
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
News Preview
Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
LGND
LISTED
NASDAQ
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
News Preview
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Monthly Fact Sheet as at 30 November 2025
News Preview
Worldwide Healthcare Trust PLC
(the "Company")
9 December 2025
LEI: 5493003YBCY4W1IMJU04
Monthly Fact Shee...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
TERN
LISTED
NASDAQ
Terns Announces Proposed Public Offering
News Preview
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has commenced a proposed underwritten public offering of $400 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded w...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
